Protara Therapeutics
TARA
25 hedge funds and large institutions have $13.2M invested in Protara Therapeutics in 2016 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 2 reducing their positions, and 10 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 2
1.06% more ownership
Funds ownership: 0% → 1.06% (+1.1%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
14% less funds holding
Funds holding: 29 → 25 (-4)
40% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 10
83% less capital invested
Capital invested by funds: $75.8M → $13.2M (-$62.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$718K |
| 2 |
PA
Perceptive Advisors
New York
|
+$515K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$350K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
+$250K |
| 5 |
Renaissance Technologies
New York
|
+$241K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$15.2M |
| 2 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
-$1.98M |
| 3 |
DM
Deerfield Management
New York
|
-$1.88M |
| 4 |
Principal Financial Group
Des Moines,
Iowa
|
-$1.72M |
| 5 |
TAM
Tiverton Asset Management
Wilimington,
Delaware
|
-$1.51M |
TARA Hedge Fund Activity: Q4 2016 in Review
25 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Protara Therapeutics (TARA) for Q4 2016, worth a combined $13.2M — down 83% from $75.8M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of TARA and 6 opened new positions — a net loss of 4 holders — while 2 trimmed existing stakes and 8 added.
The largest buyer was Baker Bros. Advisors, adding an estimated $718K. The largest seller was RA Capital Management, exiting entirely with an estimated $15.2M sold.
- 25 institutional investors held Protara Therapeutics (TARA) as of Q4 2016, down from 29 in Q3 2016.
- Funds reported $13.2M of Protara Therapeutics stock for Q4 2016, down 83% quarter-over-quarter.
- 6 funds opened new Protara Therapeutics positions in Q4 2016 and 10 closed out, a net change of -4 holders.
- The largest Protara Therapeutics buyer in Q4 2016 was Baker Bros. Advisors, an estimated $718K added.
- The largest Protara Therapeutics seller in Q4 2016 was RA Capital Management, an estimated $15.2M sold.
Based on aggregated 13F filings for Q4 2016.